The 800-Lb. Gorilla: Drug Costs Loom Large In Medicare Oncology Care Model
Executive Summary
Drug costs make up 60% of the total cost of cancer care, participants in the Medicare Oncology Care Model have found. But efforts to manage spending under the demonstration have so far focused instead on areas that represent a smaller portion of overall costs, such as hospitalizations.
You may also be interested in...
US Medicare Oncology Demo Should Test Value-Based Drug Pricing – Providers
Community Oncology Alliance proposes updates to the Oncology Care Model demonstration project, including a sharper focus on lowering prescription drug costs.
Drug Use May Shift Under US Medicare Oncology Care Model; Here’s How
‘Episode of care’ payment model could reduce off-label cancer drug prescribing but also offers an opportunity for increased use of high-value drugs, including those that can reduce costs by decreasing hospitalizations, University of Chicago’s Rena Conti suggests.
340B Dispute Resolution Process On Ice As Feuds Between Pharma, Providers, HHS Heat Up
Biden Administration’s regulatory freeze suspends HHS action to appoint an administrative dispute resolution board for the 340B program. Good news for manufacturers?
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: